These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 23376714)
1. Development and evaluation of a novel anti-colorectal cancer monoclonal antibody, WL5. Liu J; Di G; Wu CT; Hu X; Duan H Biochem Biophys Res Commun; 2013 Mar; 432(2):370-7. PubMed ID: 23376714 [TBL] [Abstract][Full Text] [Related]
2. Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characterization of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis. Woodhouse CS; Morgan AC Cancer Res; 1989 May; 49(10):2766-72. PubMed ID: 2713860 [TBL] [Abstract][Full Text] [Related]
3. Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice. Mount PF; Sutton VR; Li W; Burgess J; McKEnzie IF; Pietersz GA; Trapani JA Cancer Res; 1994 Dec; 54(23):6160-6. PubMed ID: 7954462 [TBL] [Abstract][Full Text] [Related]
4. [Expression of tumor-associated antigen LEA and its significance for pathological diagnosis]. Feng H; Song JD Ai Zheng; 2002 Jun; 21(6):658-62. PubMed ID: 12452070 [TBL] [Abstract][Full Text] [Related]
5. Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer. Green SK; Karlsson MC; Ravetch JV; Kerbel RS Cancer Res; 2002 Dec; 62(23):6891-900. PubMed ID: 12460904 [TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for recurrent colorectal cancers with human monoclonal antibody SK-1. Koda K; Glassy MC; McKnight ME; Yasutomi J; Saito N; Dan M; Nakajima N Anticancer Res; 2001; 21(1B):621-7. PubMed ID: 11299816 [TBL] [Abstract][Full Text] [Related]
7. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents. Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233 [TBL] [Abstract][Full Text] [Related]
8. Generation, immunologic characterization and antitumor effects of human monoclonal antibodies for carcinoembryonic antigen. Imakiire T; Kuroki M; Shibaguchi H; Abe H; Yamauchi Y; Ueno A; Hirose Y; Yamada H; Yamashita Y; Shirakusa T; Ishida I; Kuroki M Int J Cancer; 2004 Feb; 108(4):564-70. PubMed ID: 14696121 [TBL] [Abstract][Full Text] [Related]
9. Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas. Liao SK; Horton L; Flahart RE; O'Rear L; Crumpacker D; Imbaratto JW; Yannelli JR; Robinson RR; Oldham RK Hum Antibodies Hybridomas; 1990; 1(2):66-76. PubMed ID: 2103354 [TBL] [Abstract][Full Text] [Related]
10. Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy. Hubert P; Heitzmann A; Viel S; Nicolas A; Sastre-Garau X; Oppezzo P; Pritsch O; Osinaga E; Amigorena S Cancer Res; 2011 Aug; 71(15):5134-43. PubMed ID: 21697279 [TBL] [Abstract][Full Text] [Related]
11. ES1, a new lung carcinoma antibody--an immunohistochemical study. Mai KT; Perkins DG; Zhang J; Mackenzie CR Histopathology; 2006 Nov; 49(5):515-22. PubMed ID: 17064298 [TBL] [Abstract][Full Text] [Related]
12. Generation of an anti-EpCAM antibody and epigenetic regulation of EpCAM in colorectal cancer. Liao MY; Kuo MY; Lu TY; Wang YP; Wu HC Int J Oncol; 2015 Apr; 46(4):1788-800. PubMed ID: 25652097 [TBL] [Abstract][Full Text] [Related]
13. Characterization of the colorectal antigen IOR C2.II. Vázquez AM; Tormo B; Velandia A; Gómez CA; Alfonso M; Giscombe R; Ansotegui I; Jeddi-Tehrani M; Pérez R; Mellstedt H Year Immunol; 1993; 7():137-45. PubMed ID: 7690506 [No Abstract] [Full Text] [Related]
14. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model. Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050 [TBL] [Abstract][Full Text] [Related]
15. Recombinant chimeric antibody hCAb as a novel anti-human colorectal carcinoma agent. Xiong H; Li L; Liang QC; Bian HJ; Tang J; Zhang Q; Mi L; Chen ZN Mol Med; 2006; 12(9-10):229-36. PubMed ID: 17225871 [TBL] [Abstract][Full Text] [Related]
16. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes. de Palazzo IG; Gercel-Taylor C; Kitson J; Weiner LM Cancer Res; 1990 Nov; 50(22):7123-8. PubMed ID: 2146012 [TBL] [Abstract][Full Text] [Related]
17. Development of an in vivo antibody-mediated killing (IVAK) model, a flow cytometric method to rapidly evaluate therapeutic antibodies. Guyre CA; Gomes D; Smith KA; Kaplan JM; Perricone MA J Immunol Methods; 2008 Apr; 333(1-2):51-60. PubMed ID: 18314132 [TBL] [Abstract][Full Text] [Related]
18. Isolation of functional single domain antibody by whole cell immunization: implications for cancer treatment. Baral TN; Murad Y; Nguyen TD; Iqbal U; Zhang J J Immunol Methods; 2011 Aug; 371(1-2):70-80. PubMed ID: 21741385 [TBL] [Abstract][Full Text] [Related]
19. Production of anti-tumor human monoclonal antibodies using different approaches. Liu H; Xu ZL; Wang Y; Yang L; Feng O; Li Y; Wang YM; Zhang GG Hum Antibodies Hybridomas; 1993 Jan; 4(1):2-8. PubMed ID: 8381684 [TBL] [Abstract][Full Text] [Related]
20. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Fagerberg J; Hjelm AL; Ragnhammar P; Frödin JE; Wigzell H; Mellstedt H Cancer Res; 1995 May; 55(9):1824-7. PubMed ID: 7728746 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]